Hormonal
In older men, higher plasma dihydrotestosterone (DHT) levels (above the median) are associated with significantly reduced ischemic heart disease (IHD) mortality, independent of testosterone levels.
For older men, higher natural levels of DHT (the metabolite of testosterone) are linked to a lower risk of dying from heart disease. This suggests that the conversion of testosterone to DHT may have cardioprotective benefits, although this does not necessarily mean exogenous DHT supplementation is safe or recommended without medical supervision.
Higher DHT was associated with lower IHD mortality... Q3:Q1, adjusted HR = 0.58, P = .002; Q4:Q1, HR = 0.69, P = .026.
Why this rating
Robust observational data with precise assays and adjustment for confounders, but still observational.
Source
In Older Men an Optimal Plasma Testosterone Is Associated With Reduced All-Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality
Bu B. Yeap et al. · The Journal of Clinical Endocrinology & Metabolism · 2013
DOI 10.1210/jc.2013-3272
More from this paper
- In older men (aged 70-89), mid-range plasma testosterone levels (specifically the 2nd and 3rd quartiles, approx. 9.8–15.8 nmol/L) are associated with the lowest all-cause mortality, indicating a U-shaped relationship where both very low and very high levels carry higher risk.Good
- Plasma estradiol (E2) levels are not associated with all-cause or ischemic heart disease (IHD) mortality in older men.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →